Myelofibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK inhibitors ruxolitinib (Incyte), fedratinib (Bristol Myers Squibb), pacritinib (CTI BioPharma), and momelotinib (GSK) are the only drugs approved to treat MF in the United States and EU5 (pacritinib and momelotinib only in the United States). Although JAK inhibitors offer a therapeutic option, they are associated with high discontinuation rates and are unable to address all MF symptoms. Therefore, significant market opportunity remains for safe and tolerable treatments that can effectively manage the full spectrum of MF symptoms (thus reducing the need for polypharmacy) and that can treat MF patients with thrombocytopenia and anemia.
QUESTIONS ANSWERED
- What are the sizes of the U.S. and EU5 diagnosed prevalent and incident primary and secondary MF populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary MF?
- What is the current treatment landscape for MF? What are physicians’ experience and satisfaction with current therapies?
- How have ruxolitinib and fedratinib been integrated into the MF treatment algorithm? How will these drugs compete in the treatment of MF?
- What are the key unmet needs and areas of commercial opportunity for MF? How will novel therapies impact the treatment algorithm for MF, and which MF patients will be served by these treatment options in 2032?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
